Pharmaceuticals

Roxadustat Market 2026–2035 expanding with anemia treatment demand

March 24, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Roxadustat Market Over The Period 2026–2030?

The roxadustat market size has experienced robust growth in recent years. It is projected to increase from $6.86 billion in 2025 to $7.33 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. The historical expansion can be attributed to several factors including the high prevalence of chronic kidney disease, a reliance on erythropoiesis-stimulating agents, hospital-based anemia management, limited availability of oral anemia therapies, and the growth in dialysis centers.

The roxadustat market size is anticipated to experience substantial growth in the coming years. It is projected to attain a value of $9.56 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion during the forecast period is primarily driven by factors such as the increasing global prevalence of anemia, a growing preference for oral treatment options, the expanding population of chronic kidney disease (CKD) patients, the rise in outpatient management of anemia, and improved access to innovative anemia medications. Key developments anticipated in this period include an escalating embrace of oral anemia therapies, the increasing deployment of HIF-PHI drugs, a heightened emphasis on CKD-associated anemia, a transition away from injectable ESAs, and broader availability of anemia treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

What Drivers Are Expected To Influence The Roxadustat Market During The Forecast Period?

The increasing prevalence of chronic kidney disease (CKD) is anticipated to propel the expansion of the Roxadustat market moving forward. Chronic kidney disease is a long-term condition characterized by a progressive loss of kidney function, often leading to kidney failure if left unaddressed. The global rise in individuals affected by chronic kidney disease stems from factors such as aging populations, escalating rates of diabetes and hypertension, and unhealthy lifestyle choices. Roxadustat aids in managing chronic kidney disease by stimulating erythropoietin production, which subsequently boosts red blood cell creation, thereby helping to mitigate anemia commonly associated with the condition and improving patients’ overall kidney function and quality of life. For instance, in June 2023, according to the Kidney Research UK, a UK-based charity, the number of individuals with CKD stages 3–5 is projected to reach 3.9 million by 2033. Therefore, the growing number of people afflicted with chronic kidney disease (CKD) is a significant driver for the Roxadustat market’s growth.

How Is The Roxadustat Market Divided Into Its Major Segments?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

How Are Trends Transforming The Roxadustat Market Landscape?

Leading firms within the roxadustat market are prioritizing the collection of real-world evidence, including observational registry studies, to confirm the enduring worth, safety profile, and usage trends of their HIF PH inhibitor treatments. This evidence encompasses clinical data gathered from everyday practice environments, external to controlled trials, to accurately represent genuine patient experiences. The roxadustat market actively facilitates this movement by funding extensive real-world investigations, which healthcare payers and regulatory bodies increasingly depend on for assessment. For example, in May 2024, Astellas Pharma, a UK based company, finalized the introduction of the WINE study through the WiNe Registry in Germany. This non-interventional cohort study systematically records clinical outcomes, dosage parameters, and hemoglobin reactions in patients receiving EVRENZO (roxadustat). The data derived from this registry aid in showcasing roxadustat’s efficacy among actual CKD patient groups and contribute to informed decisions regarding long-term reimbursement. Consequently, the development of real-world evidence is a key factor propelling the expansion of the roxadustat market.

Who Are The Prominent Organizations Shaping The Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Read the full roxadustat market report here:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

Which Region Is Forecast To Lead The Roxadustat Market In Terms Of Market Size?

North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Roxadustat Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

Browse Through More Reports Similar to the Global Roxadustat Market 2026, By The Business Research Company

Rotavators Market Report 2026

https://www.thebusinessresearchcompany.com/report/rotavators-global-market-report

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Agritech Market Report 2026

https://www.thebusinessresearchcompany.com/report/agritech-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795